# C-Reactive Protein Testing Market Size to Reach Around $3.5687 Billion by 2030 | CAGR 2.4%

C-Reactive Protein Testing Market Report

WILMINGTON, DELAWARE, UNITED STATES, February 13, 2024 /EINPresswire.com/ -- C-reactive protein (CRP), an acute phase protein is primarily induced during acute phase of an inflammatory/infectious process by the action of Interleukin IL-6 on the gene responsible for CRP transcription. C-reactive protein test is used to determine concentration of CRP in blood plasma. CRP is an acute inflammatory protein that can multiply up to 1,000-fold in areas of infection or inflammation. The test is used to determine the infection and other medical conditions. The test does not specify direct cause of inflammation, but indicates the level of inflammation caused by other factors. It is a reliable early indicator of inflammation or injury.

□□□□□ □□ □□□□ □□□□□□□□ :
Laboratory Corporation of America Holdings, Abbott Laboratories, Thermo Fisher Scientific, Inc., Zoetis Inc. (Abaxis Inc.), Merck KGAA (Millipore Sigma), Quest Diagnostics Incorporated, F. Hoffmann-La Roche AG, Horiba, Ltd., Danaher Corporation (Beckman Coulter Inc.), Randox Laboratories Limited

□□□ □□□□□□□□□ □□□□□□□□ https://www.alliedmarketresearch.com/purchase-enquiry/304

Growth of the C-reactive protein testing market is majorly driven, owing to rise in prevalence of chronic diseases such as diabetes, rheumatoid arthritis, endometriosis, cardiovascular disease, inflammatory bowel disease, and other diseases. Increase in unhealthy lifestyle, poor eating habits, rise in stress, and adoption of sedentary lifestyle has led to increase in number of chronic diseases globally.

For instance, according to the Centers for Disease Control and Prevention in 2021, one in every four adults in the U.S., which is 23.7% or approximately 58.5 million people, have arthritis. Arthritis is more common in women (23.5%) than in men (18.1%) and more common in adults with fair/poor health (40.5%) than in those with excellent/very good health (15.4%). Furthermore, prevalence of arthritis rises with age. In the coming decades, the prevalence of doctor-diagnosed arthritis is expected to rise significantly. By 2040, an estimated 78.4 million adults aged 18 and older, which is 25.9% of the projected total adult population will have doctor-diagnosed arthritis, up from 58.5 million adults from 2013 to 2015. Thus, rise of such cases is expected to significantly increase the number of CRP testing and further drive the c-reactive protein testing market growth during the forecast period.

□□□□□□□□□ □□□□□□□ □□□□□□□ https://www.alliedmarketresearch.com/request-sample/304

In addition, technological advancements for CRP testing, development, and launch of various products further drive the market growth. For instance, in September 2021, HORIBA UK Limited launched its new generation Microsemi CRP point-of-care hematology analyzer. It is nearly 25% more compact and includes improved software with network connectivity, resulting in improved usability and increased memory capacity. A new parameter, granulocytes-to-lymphocytes ratio (GLR), has been added to its suite of 20 parameters to support COVID-19 patient assessment. All of this contributes toward increased functionality of new Microsemi CRPs and diagnostic efficiency in determining whether an infection or inflammation is viral or bacterial and determining the appropriate antibiotic therapy at the point-of-care. Its delivers results in just four minutes, combined with comprehensive data management and enables clinicians to initiate more rapid treatment decisions. Thus, launch of such products further propel growth of the C-reactive protein testing market.

□□□□□□ □□□□□□□□□□□□□ □□□□□□□□ □□ □□□ □□□□□□□:

□ Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

□ Comprehensive quantitative and qualitative insights at segment and sub-segment level

□ Covid 19 impact trends and perspective

□ Granular insights at global/regional/country level

□ Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

- Blanket coverage on competitive landscape

- Winning imperatives

- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

[illegible]:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

[illegible]: https://www.alliedmarketresearch.com/library-access

[illegible]:
[illegible]
[illegible]: https://www.alliedmarketresearch.com/surgical-sealants-and-adhesives-market
[illegible]: https://www.alliedmarketresearch.com/ventricular-assist-devices-market
[illegible]: https://www.alliedmarketresearch.com/single-use-bioprocessing-material-market

[illegible]:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

□□□□□□□□ □□:

David Correa

Wilmington, Delaware, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

---